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1. Introduction  
Although research over the last decade has led to new and improved therapies for a variety 
of different diseases, anticancer drug therapy continues to have undesirable outcomes, 
including both poor response and severe toxicity. In addition to the critical need to discover 
new drugs, it is important to optimize existing therapies in order to minimize adverse 
reactions and maximize efficacy. 
In the context of the complexity of cancer disease processes, future anticancer treatments 
will have to take into account the tumour microenvironment and aim to target the different 
cellular and molecular participants encompassed in a tumour, as well as their specific 
interactions. 
In the present chapter we aimed to briefly summarize current knowledge on histamine and 
histamine receptors involvement in cancer, focusing on some recent evidence that points 
them out as a promising molecular targets and avenue for cancer drug development. On the 
basis of the role on immune system, it has been reported the efficiency of histamine as an 
adjuvant to tumour immunotherapy. In addition, we present here novel findings, 
suggesting the potential application of histamine and its ligands as adjuvants to tumour 
radiotherapy.  
2. Histamine receptors  
It is generally acknowledged that histamine is an important regulator of a plethora of 
(patho) physiological conditions and exerts its actions through the interaction with four 
histamine receptor subtypes. All these receptors belong to the family of heptahelical G-
protein coupled receptors (GPCR) and they are the H1, H2, H3 and H4 histamine receptors 
(H1R, H2R, H3R, H4R). Based on the classical pharmacological analysis H1R was proposed in 
1966 by Ash and Schild (Ash & Schild, 1966) and H2R was described in 1972 by Black et al. 
(Black et al., 1972). The third histamine receptor was discovered in 1983 by a traditional 
pharmacological approach, consisting of assessing the inhibitory effect of histamine on its 
own release from depolarized rat brain slices (Arrang et al., 1983). It was not until 2000-2001 
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that by using the H3R DNA sequence, several independent research groups identified the 
novel H4R highly expressed in immune cells (Coge et al. 2001b; Lui et al., 2001; Morse et al. 
2001; Nakamura et al., 2000; Nguyen et al. 2001; Oda et al., 2000).  
Recent studies employing human genetic variance and mice lacking specific receptors or the 
ability to generate histamine, have shown functions for the histamine pathway that extend 
well beyond the established roles. As a result, antihistamines may have wider applications 
in the future than previously predicted (Smuda & Bryce, 2011). 
 
 Agonists Antagonists/ 
Inverse agonists 
H1R Histaprodifens, 2-(3-trifluoromethylphenyl) 
histamine 
Mepyramine, cetirizine, terfenadine 
diphenhydramine, loratadine 
 
H2R Amthamine, impromidine, arpromidine Famotidine, ranitidine, cimetidine, 
roxatidine, zolantidine 
 
H3R R-()-methylhistamine, imetit, immepip Clobenpropit, thioperamide, 
iodoproxyfan 
 
H4R Clobenpropit, VUF 8430, imetit, 
4-methylhistamine, R-()-methylhistamine, 
OUP-16, clozapine 
Thioperamide, JNJ7777120, VUF 
6002, A-987306, A-940894 
Table 1. Compounds most widely used in histamine receptor investigation  
Like most other GPCR, histamine receptors exist as equilibrium between their inactive and 
active conformations. Constitutive activity has now been shown for all four types of 
histamine receptors, leading to the reclassification of some antagonists as inverse agonists. 
These members of the GPCR family may exist as homo- and hetero-oligomers at the cell 
surface, which could have different pharmacological and physiological effects (Bongers et 
al., 2007; Fukushima et al., 1997; Hancock et al., 2003; Leurs et al., 2002, 2009). Moreover, the 
affinity of histamine binding to different histamine receptors varies significantly. Thus, the 
effects of histamine and receptor ligands upon receptor stimulation are rather complex.  
Pharmacologic agents are summarized in table 1.  
2.1 Histamine H1R 
Since histamine is considered to be the most important mediator in allergies such as allergic 
rhinitis, conjunctivitis, atopic dermatitis, urticaria, asthma and anaphylaxis, the most 
commonly used drugs to treat these pathological disorders are antihistamines acting on the 
H1R. In the lung, it mediates bronchoconstriction and increased vascular permeability. The 
H1R is expressed in a wide variety of tissues, including airway and vascular smooth muscle, 
endothelia, gastrointestinal tract, liver, genitourinary and cardiovascular systems, central 
nervous system (CNS), adrenal medulla, chondrocytes and in various immune cells 
including neutrophils, monocytes, eosinophils, dendritic cells (DC), as well as T and B 
lymphocytes, in which it mediates the various biological manifestations of allergic 
responses. The coding sequence of the human H1R is intronless and is located in the 
chromosome 3 (Bakker et al., 2001; Dy & Schneider, 2004; Leurs et al., 1995). The human H1R 
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contains 487 amino acids and is a Gǂq/11-coupled protein with a very large third 
intracellular loop and a relatively short C-terminal tail. The most important signal induced 
by ligand binding is the activation of phospholipase C (PLC)-generating inositol 1,4,5-
triphosphate (Ins (1,4,5) P3) and 1,2-diacylglycerol leading to increased cytosolic calcium. In 
addition to the inositol signalling system, H1R activation could lead to additional secondary 
signalling pathways. This rise in intracellular calcium levels seems to account for the various 
pharmacological activities promoted by the receptor, such as nitric oxide production, 
vasodilatation, liberation of arachidonic acid from phospholipids and increased cyclic 
guanosine-3’,5’-monophosphate (cGMP). Additionally, it was reported that H1R can directly 
increase the cyclic adenosine-3’,5’-monophosphate (cAMP) levels (Davio et al., 1995). H1R 
also activates NF-kB through Gǂq11 and GǃǄ upon agonist binding, while constitutive 
activation of NF-kB occurs only through the GǃǄ (Bakker et al., 2001; Leurs et al., 1995; Smit 
et al., 1999). Recently, it was reported that the stimulation of H1R induced H1R gene 
expression through protein kinase C ǅ (PKCǅ) activation, resulting in receptor upregulation 
(Mizuguchi et al., 2011). 
2.2 Histamine H2R 
The H2R principal action from a clinical point of view is its role in stimulating gastric acid 
secretion, thus H2R antagonists are used in the relief of symptoms of gastro-oesophageal 
reflux disease treatment. The human H2R intronless gene, encodes a protein of 359 amino 
acids and is located on chromosome 5. The H2R has a ubiquitous expression as the H1R. It is 
expressed in gastric parietal cells, heart, endothelial cells, nerve cells, airway and vascular 
smooth muscle, hepatocytes, chondrocytes and immune cells, such as neutrophils, 
monocytes, eosinophils, DC, and T and B lymphocytes (Black et al., 1972; Dy & Schneider, 
2004; Leurs et al., 1995). The H2R is coupled both to adenylate cyclase via a GTP-binding 
protein Gs, and phosphoinositide second messenger systems by separate GTP-dependent 
mechanisms. However, H2R-dependent effects of histamine are predominantly mediated by 
cAMP that activates protein kinase A (PKA) enzymes phosphorylating a wide variety of 
proteins involved in regulatory processes. Activation of H2R is also associated with other 
additional signal transduction pathways including activation of c-Fos, c-Jun, PKC and 
p70S6kinase (Davio et al., 1995; Fitzsimons et al., 2002; Fukushima et al., 1997).  
2.3 Histamine H3R 
The H3R has initially been identified in both central and peripheral nervous system as a 
presynaptic receptor controlling the release of histamine and other neurotransmitters 
(dopamine, serotonine, noradrenalin, Ǆ-aminobutyric acid and acetylcholine) (Arrang et al., 
1983; Bongers et al., 2007; Leurs et al., 2005; Lovenberg et al., 1999). The H3R has gained 
pharmaceutical interest as a potential drug target for the treatment of various important 
disorders like obesity, myocardial ischemia, migraine, inflammatory diseases and several 
CNS disorders like Alzheimer’s disease, attention-deficit hyperactivity disorder and 
schizophrenia. Pitolisant (BF2.649, 1-{3-[3-(4-chlorophenyl)propoxy]propyl} piperidine, 
hydrochloride) is the first H3R inverse agonist to be introduced in the clinics. Its wake-
promotion activity was evidenced in excessive diurnal sleepiness of patients with 
narcolepsy, Parkinson's disease or obstructive sleep apnea/hypopnea (Bongers et al., 2007; 
Lebois et al., 2011; Leurs et al., 2005; Schwartz, 2011). The human H3R gene consists of either 
three exons and two introns, or four exons and three introns spanning 5.5 kb on 
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chromosome 20. Alternatively, the most 3’ intron has been proposed to be a pseudo-intron 
as it is retained in the hH3R(445) isoform, but deleted in the hH3R(413) isoform. Overall 
similarity between the H3R and the H1R and H2R amounts to only 22% and 20%, 
respectively (Bongers et al., 2007; Coge et al., 2001a; Dy & Schneider, 2004; Leurs et al., 2005; 
Tardivel-Lacombe et al., 2001; Wellendorph et al., 2002). 
The cloning of the human H3R has led to the discovery of many H3R isoforms generated 
through alternative splicing of the H3R mRNA. H3R can activate several signal transduction 
pathways, including Gi/o-dependent inhibition of adenylate cyclase that leads to inhibition 
of cAMP formation, activation of mitogen activated protein kinase pathway (MAPK), 
phospholipase A2, and Akt/protein kinase B, as well as the inhibition of the Na+/H+ 
exchanger and inhibition of K+-induced Ca2+ mobilization (Bongers et al., 2007; Coge et al., 
2001a; Leurs et al., 2005; Wellendorph et al., 2002). A negative coupling to phosphoinositide 
turnover in the human gastric cell line HGT has also been described (Cherifi et al., 1992). 
Moreover, at least 20 isoforms of the human H3R have been described and they vary in the 
length of the third intracellular loop, their distinct CNS localization, differential signalling 
pathways and ligand binding affinity, which contribute to the heterogeneity of H3R 
pharmacology (Bongers et al., 2007; Coge et al., 2001a; Hancock et al., 2003; Leurs et al., 
2005).  
2.4 Histamine H4R 
The identification by genomics-based approach of the human H4R by several groups has 
helped refine our understanding of histamine roles. It appeared to have a selective 
expression pattern restricted to medullary and peripheral hematopoietic cells including 
eosinophils, mast cells, DC, T cells and monocytes. Therefore, growing attention is directed 
towards the therapeutic development of H4R ligands for inflammation and immune 
disorders. Several lines of evidence suggest a role of the H4R in chronic inflammatory skin 
disease and the H4R might be a therapeutic target for diseases such as atopic dermatitis 
(Gutzmer et al., 2011). In addition, H4R was reported to be present on other cell types 
including intestinal epithelium, spleen, lung, stomach, CNS, nerves of nasal mucosa, enteric 
neurons and interestingly in cancer cells (Cianchi et al., 2005; Coge et al. 2001b; Connelly et 
al., 2009; Leurs et al. 2009; Lui et al., 2001; Medina et al., 2006; Morse et al. 2001; Nakamura 
et al., 2000; Nguyen et al. 2001; Oda et al., 2000). The significance of the H4R presence in 
various human tissues remains to be elucidated and therefore, new roles of H4R are still 
unrevealed (Leurs et al., 2009; Zampeli & Tiligada, 2009). The H4R cDNA was finally 
identified in the human genome database on the basis of its overall homology (37%, 58% in 
transmembrane regions) to the H3R sequence and it has a similar genomic structure. On the 
other hand, the homology with H1R and H2R is of approximately 19%. The human H4R gene 
that mapped to chromosome 18 is interrupted by two large introns and encodes a protein of 
390 amino acids (Coge et al., 2001b; Leurs et al., 2009). H4R is coupled to Gǂi/o proteins, 
inhibiting forskolin-induced cAMP formation (Nakamura et al., 2000; Oda et al., 2000). 
Additionally, stimulation of H4R leads to activation of MAPK and also increased calcium 
mobilization via pertussis toxin-sensitive pathway (Leurs et al., 2009; Morse et al., 2001). 
Isoforms have been described for the H4R which have different ligand binding and 
signalling characteristics. H4R splice variants [H4R (67) and H4R (302)] have a dominant 
negative effect on H4R (390) functionality, being able to retain it intracellularly and to 
inactivate a population of H4R (390) presumably via hetero-oligomerization (Leurs et al., 
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2009; van Rijn et al., 2008). In addition, H4R dimeric structures that include homo- and 
hetero-oligomer formation and post-translational changes of the receptor might contribute 
to added pharmacological complexity for H4R ligands (Leurs et al., 2009; van Rijn et al., 
2006, 2008). 
3. Histamine receptors in breast cancer 
An estimated 1 million cases of breast cancer are diagnosed annually worldwide. Breast 
cancer is the most common neoplastic disease in women, and despite advances in early 
detection, about 30% of patients with early-stage breast cancer have recurrent disease, which 
is metastatic in most cases and whose cure is very limited showing a 5-year survival rate of 
20% (Ferlay et al., 2010; Gonzalez-Angulo et al., 2007).  
Histamine plays a critical role in the pathologic and physiologic aspects of the mammary 
gland, regulating cell growth, differentiation and functioning during development, 
pregnancy and lactation. Among monoamines, histamine demonstrates the greatest 
proliferative activity in breast cancer (Davio et al., 1994; Malinski et al., 1993; Wagner et al., 
2003). Furthermore, histamine is increased in plasma and cancerous tissue derived from 
breast cancer patients compared to healthy group which is associated to an enhanced 
histidine decarboxylase (HDC) activity and a reduced diaminooxydase (DAO) activity that 
determine an imbalance between the synthesis and degradation of this monoamine. 
Histamine plasma level is dependent on the concentration of histamine in the tissues of 
ductal breast cancers, suggesting the participation of this monoamine in the development of 
this neoplasia (Reynolds et al., 1998; Sieja et al., 2005; von Mach-Szczypiński et al., 2009). A 
pilot study revealed that in samples of the same invasive ductal carcinoma patient, 
histamine peripheral blood levels tended to be reduced post-operatively (Kyriakidis et al., 
2009). It was reported that in experimental mammary carcinomas, histamine becomes an 
autocrine growth factor capable of regulating cell proliferation via H1R and H2R, as one of 
the first steps responsible for the onset of malignant transformation. In this light, the in vivo 
treatment with H2R antagonists produced the complete remission of 70% of experimental 
tumours (Cricco et al., 1994; Davio et al., 1995; Rivera et al., 2000). Many reports indicate the 
presence of H1R and H2R in normal and malignant tissues as well as in different cell lines 
derived from human mammary gland. H2R produced an increase in cAMP levels while H1R 
was coupled to PLC activation in benign lesions. On the other hand, H1R was invariably 
linked to PLC pathway but H2R stimulated both transductional pathways in carcinomas 
(Davio et al., 1993, 1996). However, the clinical trials with H2R antagonists demonstrated 
controversial results for breast cancer (Bolton et al., 2000; Parshad et al., 2005).  
Recently, it was demonstrated that H3R and H4R are expressed in cell lines derived from 
human mammary gland (Medina et al., 2006). Histamine is capable of modulating cell 
proliferation exclusively in malignant cells while no effect on proliferation or expression of 
oncogenes related to cell growth is observed in non-tumorigenic HBL-100 cells (Davio et al., 
2002; Medina et al., 2006). Furthermore, histamine modulated the proliferation of MDA-MB-
231 breast cancer cells in a dose-dependent manner producing a significant decrease at 10 
μmol.L-1 concentration whereas at lower concentrations increased proliferation moderately. 
The negative effect on proliferation was associated to the induction of cell cycle arrest in 
G2/M phase, differentiation and a significant increase in the number of apoptotic cells 
(Medina et al., 2006; Medina & Rivera, 2010b). Accordingly, by using pharmacological tools, 
results demonstrated that histamine increased MDA-MB-231 cell proliferation and also 
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migration via H3R. In contrast, clobenpropit and VUF8430 treatments significantly 
decreased proliferation. This outcome was associated to an induction of apoptosis 
determined by Annexin-V staining and TdT-mediated UTP-biotin Nick End labelling 
(TUNEL) assay, which was blocked by the specific H4R antagonist JNJ7777120. Also H4R 
agonists exerted a 2.5-fold increase in the cell senescence while reduced migration (Medina 
et al., 2008, 2010c, 2011b). Furthermore, histamine differentially regulates expression and 
activity of matrix metalloproteinases, cell migration and invasiveness through H2R and H4R 
in MDA-MB-231 cells modulating H2O2 intracellular levels (Cricco et al., 2011). 
In addition, histamine at all doses tested, decreased the proliferation of a more differentiated 
breast cancer cell line, MCF-7, through the stimulation of the four histamine receptor 
subtypes exhibiting a higher effect through the H4R. Treatment of MCF-7 cells with the H4R 
agonists, inhibited cell proliferation and increased apoptosis and senescence (Medina et al., 
2011b). These results represent the first report about the expression of H3R and H4R in 
human breast cells and interestingly show that the H4R is involved in the regulation of 
breast cancer cell proliferation, apoptosis, senescence, migration and invasion.  
Recent results obtained with the orthotopic xenograft tumours of the highly invasive human 
breast cancer line MDA-MB-231 in immune deficient nude mice indicate that the H4R was 
the major histamine receptor expressed in the tumour. Remarkably, in vivo JNJ7777120 
treatment (10 mg.kg-1, p.o., daily administration) significantly decreased lung metastases, 
indicating that H4R may be involved in the metastatic process (Medina & Rivera, 2010b). In 
addition, in vivo clozapine treatment (1 mg.kg-1, s.c., daily administration) significantly 
decreased tumour growth while enhanced survival of bearing tumour mice (Martinel Lamas 
et al., unpublished data).  
Recent data indicate that H3R and H4R are expressed in human biopsies of benign lesions 
and breast carcinomas being the level of their expression significantly higher in carcinomas, 
confirming that H3R and H4R are present not only in cell lines but also in the human breast 
tissue. Furthermore, the expression of H3R is highly correlated with proliferation and 
histamine production in malignant lesions while the 50% of malignant lesions expressed 
H4R, all of them corresponding to metastases or high invasive tumours (Medina et al., 2008). 
The identification of histamine receptor subtypes and the elucidation of their role in the 
development and growth of human mammary carcinomas may represent an essential clue 
for advances in breast cancer treatment. The presented evidences contribute to the 
identification of molecules involved in breast carcinogenesis and confirm the role of H4R in 
the regulation of breast cancer growth and progression representing a novel molecular 
target for new therapeutic approach. 
4. Histamine receptors in lymphomas and leukaemia 
There is increasing evidence that histamine plays a role in cell differentiation and 
proliferation in several of normal tissues and in a wide range of tumours, including 
haematological neoplasias. 
After an initial work in the late 1970s showing that histamine is able to induce 
haematopoietic stem cell proliferation via H2R (Byron, 1977), a real rush broke out in 
searching for further effects of histamine in haematopoiesis and haematological neoplasias. 
The histamine levels were determined in lymph nodes of patients with malignant 
lymphomas, Hodking´s disease (HD) or non-Hodking lymphomas (NHL), and in all cases 
the values were higher than in controls. In patients with NHL, these levels showed 
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dependence on the grade of malignancy as they found to be significantly higher in those 
classified as high-grade malignant (Belcheva & Mishkova, 1995). Immunostaining and 
ELISA method also confirmed the presence of histamine in the cytoplasm of acute 
lymphocytic leukaemia (ALL) cells, and H1R antihistamines inhibited their clonogenic 
growth. There was no correlation between the clonogenic growth of ALL cells and their 
histamine content, suggesting that while histamine may be important for the clonogenic 
growth of ALL cells; other factors also affect their clonogenity (Malaviya et al., 1996). 
Furthermore, leukaemia cell lines such as U937, expressed histamine receptors and a switch 
of histamine receptor expression from H2R to H1R during differentiation of monocytes into 
macrophages is observed (Wang et al., 2000). 
Most patients with acute myeloid leukaemia (AML) achieve complete remission after 
induction chemotherapy. Despite ensuing courses of consolidation chemotherapy, a large 
fraction of patients will experience relapses with poor prospects of long-term survival. 
Interleukin-2 (IL-2) and interferon-alpha (IFN-alpha) are effective activators of lymphocytes 
with anti-neoplastic properties, such as T-cells or natural killer (NK) cells, constituting the 
basis for their widespread used as immunotherapeutic agents in human neoplastic disease. 
The functions of intratumoural lymphocytes in many human malignant tumours are 
inhibited by reactive oxygen species (ROS), generated by adjacent monocytes/macrophages. 
In vitro data suggest that those immunotherapeutic cytokines only weakly activate T cells or 
NK cells in a reconstituted environment of oxidative stress and inhibitors of ROS formation 
or ROS scavengers synergize with IL-2 and IFN-alpha to activate T cells and NK cells. 
Recently, IL-2 therapy for solid neoplastic diseases and haematopoietic cancers has been 
supplemented with histamine dihydrochloride (Ceplene), a synthetic derivative of 
histamine, with the aim of counteracting immunosuppressive signals from 
monocytes/macrophages. Histamine dihydrochloride inhibits the formation of ROS that 
suppress the activation of T cells and NK cells by suppressing the activity of NADPH 
oxidase via H2R. When administered in addition to IL-2, histamine dihydrochloride enables 
the activation of these lymphocytes by the cytokine, resulting in tumour cell killing. This 
combination was recently approved within the EU as a remission maintenance 
immunotherapy in AML, as histamine dihydrochloride reduces myeloid cell-derived 
suppression of anti-leukemic lymphocytes, improving NK and T-cell activation. Further 
research in this area will shed light on the role of histamine with the aim to improve cancer 
immunotherapy efficacy (Hellstrand et al., 2000; Martner et al., 2010; Yang & Perry, 2011). 
5. Histamine receptors in gynaecologic cancers 
Gynaecologic cancers encompass a remarkably heterogeneous group of tumours: cervical, 
ovarian, uterine, vaginal, and vulvar cancer. It has been postulated that histamine plays a 
critical role in proliferation of normal and cancer tissues, including the mammary gland, 
ovarian and endometrium. 
In the murine uterus, the rapidly dividing epithelial cells of the endometrium can be defined 
as the major sources of histamine. In these cells the level of HDC expression is controlled 
mainly by progesterone-mediated signals which, interestingly, induce maximal level of 
HDC expression on the day of implantation (Pós et al., 2004). 
In vitro studies showed that histamine may play an important role in follicular development 
and ovulation via H1R and H2R in women, acting as apoptosis inducer, taking part in the 
selection process of the dominant follicle and stimulating ovulation (Szukiewicz et al., 2007). 
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Interestingly, histamine content increased unequivocally in ovarian, cervical and 
endometrial carcinoma in comparison with their adjoining normal tissues, suggesting the 
participation of histamine in carcinogenesis. Besides, exogenous histamine, at micromolar 
concentration, stimulated proliferation of human ovarian cancer cell line SKOV-3 (Batra & 
Fadeel, 1994; Chanda & Ganguly, 1995). Preliminary results show that H4R is expressed in 
primary and metastatic ovarian carcinoma and also in gallbladder cancer (Medina & Rivera, 
2010b). 
Histamine levels within ovarian tissue during the oestrus may correspond to cyclic changes 
of mast cells content and distribution in the ovary, suggesting an involvement of these cells 
in local regulation of ovarian function (Adyin et al., 1998; Nakamura et al., 1987). 
Interestingly, mast cells can typically be found in the peritumoural stroma of cervix 
carcinomas, as well as in many other cancers. Furthermore, high numbers of active, 
degranulated mast cells have been described in HPV infections and cervical intraepithelial 
neoplasias (Cabanillas-Saez et al., 2002; Demitsu et al., 2002). Hence, a functional 
relationship between mast cells and tumour cells has been proposed, where mast cells are 
involved in stimulating tumour growth and progression by enhancing angiogenesis, 
immunosuppression, mitogenesis, and metastasis (Chang et al., 2006). Mast cell activation 
leads to the release of inflammatory mediators, including histamine. Increased histamine 
levels have been described in the cervix lesions, where they have been associated with 
tumour growth and progression. Moreover, histamine receptors have been reported in 
different cell lines and tissues derived from experimental and human cervical neoplasias. 
The functional significance of immune cell infiltration of a tumour, specifically of mast cells 
located at the periphery of several neoplasias, is still a matter of controversy. Histamine 
acting via H1R in cervical cancer cells could be pro-migratory, but when acting via H4R 
could inhibit migration. On the other hand, other results also showed that cervical 
carcinoma cell mediators can activate mast cells to degranulate, demonstrating an active and 
dynamic cross-talk between tumour cells and infiltrating mast cells as shown in 
morphologic studies of neoplastic tissues (Rudolph et al., 2008). 
In the light of these results, further investigations have to be done in order to elucidate the 
physiological role of histamine receptors on cell proliferation, as well as its implication in 
gynaecologic cancer progression with a potential interest for cancer treatment. 
6. Histamine receptors in colorectal cancer 
Colorectal cancer is one of the leading causes of cancer death among both men and women 
worldwide (Ferlay et al., 2010). It has been previously described that the histamine 
catabolising enzymes, DAO or histamine N-methyltransferase (HNMT), activities were 
significantly lower in adenoma tissue than in healthy mucosa in the same patients (Kuefner 
et al., 2008). Furthermore, HDC expression and its activity are increased in many human 
tumours including colorectal cancer (Cianchi et al., 2005; Masini et al., 2005; Reynolds et al., 
1997). The levels of histamine were elevated in colon carcinoma and this is directly related to 
an increase in HDC expression and a decrease in DAO activity (Chanda & Ganguly, 1987). 
Also, the distribution of histamine receptors in the normal intestinal tract was reported 
(Sander et al., 2006). It was showed the expression pattern of H1R, H2R and H4R in intestinal 
tract, receptors that were over expressed in the colon of patients with irritable bowel 
syndrome and food allergies. Furthermore, the H3R was not detected in intestinal tissue 
(Sander et al., 2006). This data was further confirmed by Boer K et al, that also demonstrated 
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a decreased of H1R and H4R protein levels in colorectal cancer while the levels of the H2R 
were not modified compared to normal colon mucosa (Boer et al., 2008).  
It was described that the H1R antagonist, loratadine, inhibited proliferation and enhanced 
radiosensitivity in human colon cancer cells (Soule et al., 2010). Also the H2R seems to be 
implicated in the proliferation of colon cancer. In 1994 Adams, showed that in vivo and in 
two human colonic adenocarcinoma cell lines, C170 and LIM2412, cell proliferation induced 
by histamine in a dose dependent manner was blocked by H2R antagonist, cimetidine 
(Adams et al., 1994). Ranitidine, another H2R antagonist, also showed to extend the survival 
of patients who were under surgery of colorectal cancer (Nielsen et al., 2002). It is well 
known the effects of histamine in the immune system, according to this it was demonstrated 
that patients receiving cimetidine or famotidine before curative resection augmented the 
probabilities of having tumour infiltrating lymphocytes in their tumours than control 
patients (Adams & Morris, 1996; Kapoor et al., 2005). Furthermore, earlier studies 
demonstrated that histamine induced in vitro and in vivo cell proliferation and this outcome 
was blocked by H2R antagonists (Adams et al., 1994; Cianchi et al., 2005). This effect was 
associated with the attenuation of anti-tumour cytokine expression in the tumour 
microenvironment exerted by histamine, thus resulting in stimulated colorectal cancer 
growth (Takahashi et al., 2001; Tomita & Okabe, 2005). In addition, H2R antagonist 
significantly suppressed the growth of tumour implants in mice by inhibiting angiogenesis 
via reducing VEGF expression (Tomita et al., 2003).  
As it was described above, the expression of the H4R seems to be suppressed in human 
colorectal cancer. It was also demonstrated that the levels of the H4R are reduced in 
advanced colorectal cancer compared with those in an initiating state, which suggest that 
the H4R expression is regulated during the progression of the disease (Fang et al., 2011). The 
stimulation in vitro of the H4R by a specific agonist induced an augmented expression of the 
p21Cip1 and p27 Kip1 proteins, producing an increase of arrested cells in the G1 phase. It has 
been proposed that prostaglandin E2 (PGE-2), the main product of the cyclooxygenase-2 
activity, is implicated in colorectal cancer development. In this line, it has been 
demonstrated that histamine is fully implicated in the production of PGE-2 by its two 
receptors H2R and H4R in two human colon carcinoma cell lines (Cianchi et al., 2005). 
Histamine effect can be blocked by zolantidine, an H2R antagonist, and also by JNJ7777120, 
an H4R antagonist, whereas mepyramine, an H1R antagonist, has no effect on the production 
of PGE-2. Furthermore, JNJ7777120 inhibited the cell growth induced by histamine in three 
different human colon cancer cell lines and also inhibited the histamine-mediated increase 
in VEGF in two cell lines. Combined treatment with zolantidine (an H2R antagonist) and 
JNJ7777120 determined an additive effect on reducing the histamine-induced VEGF 
production and histamine-stimulated proliferation (Cianchi et al., 2005), suggesting the 
involvement of H4R in colon carcinogenesis (Boer et al., 2008). 
7. Histamine receptors in melanoma 
Malignant melanoma arises from epidermal melanocytes and despite being the cause of less 
than 5% of skin cancers, it is responsible for the large majority of skin cancer deaths (Ferlay 
et al., 2010). Early detection is vital for long-term survival, given that there is a direct 
correlation between tumour thickness and mortality (Cummins et al., 2006).  
Melanoma cells but not normal melanocytes contain large amounts of histamine that has 
been found to accelerate malignant growth (Pós et al., 2004). The absence of expression of 
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HDC in Mel-5 positive melanocytes isolated from skin samples of healthy persons, suggest 
that the level of HDC is strongly associated with malignancy in the skin (Haak-Frendscho et 
al., 2000). As a functional consequence of the inhibition of HDC protein synthesis, specific 
antisense oligonucleotide strongly (> 50%) decreased the proliferation rate of both 
WM938/B and HT168/91 human melanoma cells. Similar effects were found with other two 
melanoma cell lines WM35 and M1/15, suggesting that endogenous histamine may act as an 
autocrine growth factor (Hegyesi et al., 2000). On the other hand, overexpression of HDC 
markedly accelerated tumour growth and increased metastatic colony-forming potential 
along with rising levels of local histamine production that was correlated with tumour H2R 
and rho-C expression in mouse melanoma (Pós Z et al., 2005). 
It has been previously reported the expression of H1R, H2R and H3R in melanoma cell lines 
(Hegyesi et al., 2005). In addition, it was described that in human melanoma cells, histamine 
acting through the H1R decreases cell proliferation, whereas it enhances growth when acting 
through the H2R (Lázar-Molnar et al., 2002). Furthermore, there is no evidence of mitogenic 
signalling through the H3R in human melanoma (Hegyesi et al., 2005). 
H1R function is involved in chemotaxis via PLC activation, and its subsequent intracellular 
calcium mobilization. Proliferation assays showed that histamine exerted a concentration 
dependent dual effect on proliferation of the WM35 primary melanoma cell line. High 
concentrations of histamine (10-5 M) had an inhibitory effect while lower concentrations (10-
7 M) increased colony formation. Similar results were achieved when using H1R agonist 2-(3-
fluoromethylphenyl)histamine and H2R agonist arpromidine, respectively. The use of 
ranitidine, famotidine and cimetidine, all H2R specific antagonists, abolished the stimulatory 
effect of histamine on cell proliferation, indicating the participation of H2R in this mitogenic 
role of histamine. Second messenger measurement indicated that H2R are linked to cAMP 
production, thus suggesting an involvement of PKA in the mitogenic pathway triggered in 
this system, which is corroborated by the fact that forskolin and permeable cAMP analogues 
also produce a dose-dependent increase on cell proliferation (Lázar-Molnar et al., 2002). 
Numerous in vivo studies employing animal models bearing syngenic or xenogenic 
melanoma grafts demonstrated that both endogenous and exogenous histamine have the 
ability to stimulate tumour growth while H2R antagonists (e.g. cimetidine, famotidine, 
roxatidine) inhibited this effect (Pós et al., 2005; Szincsák et al., 2002; Tomita et al., 2005; 
Uçar, 1991). Additionally, H2R antagonists stimulated melanogenesis and inhibited 
proliferation in B16-C3 mouse melanoma cells (Uçar, 1991). It was also found that melanoma 
tumour growth was not modulated by in vivo histamine treatment while treatment with 
terfenadine, an H1R antagonist, in vitro induced melanoma cell death by apoptosis and in 
vivo significantly inhibited tumour growth in murine models (Blaya et al., 2010).  
Differences between melanoma cells in their capacity to produce and degrade histamine 
could explain the different sensitivities of melanoma cell types to exogenous histamine 
treatment. Moreover, there is evidence that cytokines can influence HDC expression and 
activity. It has been shown that there is a regulation loop between interleukin 6 (IL-6) and 
histamine: histamine increased IL-6 expression and secretion in metastatic lines via the H1R, 
and IL-6 treatment increased the HDC and histamine content in primary melanoma lines 
(Lázar-Molnar et al., 2002). Interferon-gamma (IFN-gamma) produced by surrounding 
immune cells decreases HDC expression, affecting melanoma growth and also impairs 
antitumour activity of the immune system, then contributing to the escape of melanoma 
cells from immunosurveillance (Horváth et al., 1999; Heninger et al., 2000). Furthermore, 
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mast cell activation initiates upon ultraviolet-B irradiation, which triggers histamine 
secretion acts as a cellular immunity suppressor (Chang et al., 2006).  
Moreover, the role of histamine in local immune reactions was further supported by the 
results of Hellstrand et al., who found that histamine can inhibit the ROS formation of 
monocytes/macrophages in the tumour (Hellstrand et al., 2000). This may explain the 
clinical benefit demonstrated by histamine (Ceplene) as an adjuvant to immunotherapy with 
IL-2 in several phase II and III clinical trials in metastatic melanoma (Agarwala, 2002). The 
addition of histamine dihydrochloride to an outpatient regimen of IL-2 is safe and well 
tolerated and demonstrates a survival advantage over IL-2 alone (9.4 vs. 5.1 months) in 
melanoma patients with liver metastases (Agarwala, 2002). However, a second confirmatory 
phase III study failed to show any survival benefit for those patients (Naredi, 2002).  
Besides, Medina et al. showed that exogenous histamine modulated the activity of the 
antioxidant enzymes, increasing superoxide dismutase while decreasing catalase activity in 
WM35 melanoma cells. Accordingly, histamine treatment markedly augmented the levels of 
hydrogen peroxide and diminished those of superoxide anion, indicating that the imbalance 
of antioxidant enzymes leads to the cell proliferation inhibition (Medina et al., 2009). 
Furthermore, it was demonstrated that WM35 and M1/15 melanoma cells express H4R at 
the mRNA and protein level. By using histamine agonists and antagonists it was shown that 
the inhibitory effect of histamine on proliferation was in part mediated through the 
stimulation of the H4R. Treatment with a specific H4R antagonist, JNJ7777120 and the use of 
siRNA specific for H4R mRNA blocked the decrease in proliferation triggered by the H4R 
agonists. Furthermore, the decrease in proliferation exerted by H4R agonists was associated 
with a 2-fold induction of cell senescence and an increase in melanogenesis that is a 
differentiation marker on these cells (Massari et al., 2011). Current studies indicate that the 
H4R is expressed in the 42% of human melanoma biopsies of different histopathological 
types, showing cytoplasmic localization and confirming that the H4R is present not only in 
these cell lines but also in human melanoma tissue (Massari et al., 2011). 
The in vivo subcutaneous daily 1 mg.kg-1 histamine or 1 mg.kg-1 clozapine (H4R agonist) 
injections of M1/15 melanoma cell tumour bearing nude mice showed a survival increase 
vs. control group (treated with saline solution). Besides, results showed an antitumour effect 
of histamine and clozapine, including suppression of tumour growth (Massari et al., 
unpublished data). Further studies are needed to corroborate the H4R importance as 
potential target for new drug development for the treatment of this disease. 
8. Histamine as a potential adjuvant to radiotherapy  
8.1 Radioprotectors 
Radiotherapy is the most common modality for treating human cancers and relies on 
ionising radiation induced DNA damage to kill malignant cells. Eighty percent of cancer 
patients need radiotherapy at some time or other, either for curative or palliative purpose. 
To optimise results, a cautious balance between the total dose of radiotherapy delivered and 
the threshold limit of the surrounding normal critical tissues is required. In order to obtain 
better tumour control with a higher dose, the normal tissues should be protected against 
radiation damage. Therefore, the role of radioprotective compounds is of utmost importance 
in clinical radiotherapy (Hall & Giaccia, 2006; Mah et at., 2011). Ionising radiation causes 
damage to living tissues through a series of molecular events. DNA double-strand breaks 
(DSBs), which are exceptionally lethal lesions, can be formed either by direct energy 
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deposition or indirectly through the radiolysis of water molecules, which generate clusters 
of ROS that react with DNA molecules. Because human tissues contain 80% water, the major 
radiation damage produced by low linear transfer energy (LET) radiation is due to the 
aqueous free radicals. DSBs are essentially two single stranded nicks in opposing DNA 
strands that occur in close proximity, severely compromising genomic stability (Grdina, 
2002; Hall & Giaccia, 2006; Mah et at., 2011). A series of complex pathways collectively 
known as the DNA damage response (DDR) is responsible for the recognition, signalling 
and repair of DSBs in cells, ultimately resulting in either cell survival or cell death (Mah et 
at., 2011). These free radicals react not only with DNA but also with other cellular 
macromolecules, such as RNA, proteins, membrane, etc, and cause cell dysfunction and 
mortality. Unfortunately, these reactions take place in tumour as well as normal cells when 
exposed to radiation. Therefore, to improve the efficacy of radiotherapy there is an intense 
interest in combining this modality with ionising radiation modifiers, such as 
radioprotectors. These compounds mitigate damage to surrounding non-malignant tissue 
(Brizel, 2007; Grdina, 2002; Hall & Giaccia, 2006; Hosseinimehr, 2007).  
The most remarkable group of true radioprotectors is the sulfhydryl compounds. The 
simplest is cysteine, a sulfhydryl compound containing a natural amino acid (Table 2). In 
1948, Patt discovered that cysteine could protect mice from the effects of total-body 
exposure to X-rays if the drug was injected or ingested in large amounts before the radiation 
exposure. At about the same time, in Europe independently discovered that cysteamine 
could also protect animals from total-body irradiation (Table 2). However, cysteine is toxic 
and induces nausea and vomiting at the dose levels required for radioprotection. A 
developmental program was initiated in 1959 and conducted at the Walter Reed Institute of 
Research to identify and synthesize drugs capable of conferring protection to individuals in 
a radiation environment by the U.S. Army. Over 4.000 compounds were synthesized and 
tested and it was discovered that the covering of the sulfhydryl group by a phosphate group 
reduced toxicity (Grdina, 2002; Hall & Giaccia, 2006; Nucifora et al., 1972). 
The concept of the therapeutic ratio is central to understanding the rationale for using 
radioprotectors. It relates tumour control probabilities and normal tissue complication 
probabilities to one another. An ideal radioprotector will reduce the latter without 
compromising the former and should also be minimally toxic itself. Radioprotective 
strategies can be classified under the categories of protection, mitigation, and treatment. 
Protectors are administered before radiotherapy and are designed to prevent radiation-
induced injury. Amifostine is the prototype drug (Table 2). Amifostine is the only 
radioprotective agent that is approved by FDA for preventing of xerostomia induced by 
gamma irradiation in patients under radiotherapy (Grdina et al., 2009; Hall & Giaccia, 2006; 
Hosseinimehr, 2007; Kouvaris et al., 2007, Wasserman & Brizel, 2001). Its selectivity for 
normal tissue is due to its preferential accumulation in normal tissue compared to the 
hypoxic environment of tumour tissues with low pH and low alkaline phosphatase, which 
is required to dephosphorylate and activate amifostine (Calabro-Jones et al., 1985; Grdina, 
2002; Mah et at., 2011). The active metabolite, WR-1065 scavenges free radicals and is 
oxidised, causing anoxia or the rapid consumption of oxygen in tissues. This sulfhydryl 
compound is one of the most effective radioprotectors known nowadays, but there are two 
main problems of its using. The first one is their toxicity and the second is the short-ranged 
activity. Amifostine is also the unique radioprotector widely used in clinic on chemotherapy 
applications (Grdina et al., 2009; Hall & Giaccia, 2006; Hosseinimehr, 2007). 
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COMPOUND SIDE EFFECTS CHEMICAL STRUCTURE 
Amifostine (WR-2721) Drowsiness, feeling of coldness, flushing/feeling 
of warmth; hiccups, nausea, sneezing, vomiting 
 
Cysteamine 
 
Depression, stomach or intestinal ulcer and 
bleeding, liver problems, skin condition, 
decreased calcification of bone, seizures, broken 
bone, decreased white blood cells 
 
 
Palifermin Skin rash, flushing, unusual sensations in the 
mouth (tingling, tongue thickness) 
 
C721-H-1142-N-202-O204-S9 
Cysteine Toxic, nausea, vomiting 
 
Tempol Constipation; diarrhoea, severe allergic reactions 
(rash; hives; itching; difficulty breathing; 
tightness in the chest; swelling of the mouth, face, 
lips, or tongue), loss of appetite, muscle 
weakness, nausea, slow reflexes, vomiting  
 
Table 2. Radioprotectors. Extracted and modified from http://www.wolframalpha.com/ 
entities/chemicals/palifermin/hs/j8/6k/; http://www.drugs.com 
Mitigants are administered after radiotherapy but before the phenotypic expression of 
injury and are intended to ameliorate injury. The keratinocyte growth factor (KGF), 
palifermin, has been approved as a new, targeted therapy for the prevention of severe oral 
mucositis in patients with head and neck cancer undergoing post-operative 
radiochemotherapy and can be considered as the prototype mitigant (Weigelt et at., 2011) 
(Table 2). Palifermin, like the natural KGF, helps maintain the normal structure of the skin 
and gastrointestinal surface (lining) by stimulating cells to divide, grow and develop (Le et 
at., 2011; Weigelt et at., 2011). 
Treatment is a strategy that is predominantly palliative and supportive in nature. 
Pharmacologic radioprotective strategies should be integrated with physical strategies such 
as intensity-modulated radiotherapy to realize their maximum clinical potential (Hall & 
Giaccia, 2006; Le et al., 2011). 
In addition, low-to-moderate doses of some agents such as nitroxides, adrenoceptor agonist, 
were found to have radioprotective activity in experiments but their application in clinic 
remains doubtful. Tempol (4-hydroxy-2,2,6,6-tetramethyl-piperidinyloxy) belongs to a class 
of water-soluble nitroxides which are membrane-permeable stable free radical compounds 
that confer protection against radiation-induced damage (Bennett et at., 1987; Mah et at., 
2011; Muscoli et at., 2003) (Table 2). It is thought to elicit its effects through the oxidation of 
reduced transition metals, scavenging free radicals and mimicking superoxide dismutase 
activity (Jiang et al., 2007).  
8.2 Histamine as a radioprotector 
Despite many years of research there are surprisingly few radiation protectors in use 
today, whose clinical value is limited due to their toxicity; thus, the development of 
effective and nontoxic agents is yet a challenge for oncologists and radiobiologists (Hall & 
Giaccia, 2006).  
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The acute effects of irradiation result from the death of a large number of cells in tissues 
with a rapid rate of turnover. These include effects in the epidermal layer or skin, 
gastrointestinal epithelium, and haematopoietic system, in which the response is 
determined by a hierarchical cell lineage, composed of stem cells and their differentiating 
offspring. In clinical radiotherapy, the tolerance of normal tissues for radiation depends on 
the ability of clonogenic cells to maintain a sufficient number of mature cells suitably 
structured to preserve organ function (Hall & Giaccia, 2006). During radiotherapy for intra-
abdominal and pelvic cancers, radiation seriously affects radiosensitive tissues such as small 
intestine and bone marrow (Erbyl et al., 2005; Hall & Giaccia, 2006). It was previously 
demonstrated that histamine treatment (daily subcutaneous injection, 0.1 mg.kg-1) 
significantly protects mouse small intestine against radiation-induced toxicity ameliorating 
histological injury and improving trophism of enterocytes (Medina et al., 2007). Histamine 
completely prevented the decrease in the number of crypts evoked by whole body 
irradiation, which is vital for small intestine restoration since the intestinal crypt contains a 
hierarchy of stem cells that preserve the potential to regenerate the stem cell population and 
the tissue after cytotoxic exposure (Potten et al., 2002). Histamine radioprotective effect on 
small intestine was related to an increased rate of proliferation as evidenced by the 
enhanced proliferation markers immunoreactivity [5-bromo-2’-deoxyuridine (BrdU), and 
proliferating cell nuclear antigen (PCNA)]. Additionally, this outcome was accompanied by 
a reduction in the number of apoptotic cells per crypt and a modification of antioxidant 
enzyme levels that could lead to enhance the antioxidant capacity of intestinal cells (Medina 
et al., 2007). Histamine also protects rat small intestine against ionising radiation damage 
and this effect was principally associated to a decrease in intestinal cell crypt apoptosis 
(Medina & Rivera, 2010a). 
The bone marrow pluripotent stem cells, such as erythroblast, are particularly radiosensitive 
and, after whole body irradiation, an important grade of aplasia is observed increasing the 
possibility of haemorrhage and/or infection occurrence that could be lethal. The survival of 
stem cells determines the subsequent repopulation of bone marrow after irradiation (Hall & 
Giaccia, 2006). Results demonstrated that histamine (0.1 mg.kg-1) significantly reduced the 
grade of aplasia, ameliorating the oedema and vascular damage produced by ionising 
radiation while eliciting a significant conservation of the medullar progenies on bone marrow 
in mouse and rat species, increasing the number of megakaryocytes, myeloid, lymphoid and 
erythroid cells per mm2. The histamine effect is mediated at least in part by an increase in the 
rate of proliferation, as evidenced by the enhanced PCNA protein expression and BrdU 
incorporation, and is associated with an enhanced HDC expression in irradiated bone marrow 
cells (Medina et al., 2010; Medina & Rivera, 2010a). In this line, it was reported that a faster 
bone marrow repopulation was observed in wild type in comparison with HDC-deficient mice 
and that intracellular HDC and histamine content in regenerating bone marrow populations is 
increased after total-body irradiation (Horvath et al., 2006).  
Despite improvements in the technology for delivering therapeutic radiation, salivary 
glands are inevitably injured during head and neck cancer radiotherapy, causing 
devastating side-effects which results in salivary hypofunction and consequent xerostomia 
(Burlage et al., 2008; Hall & Giaccia, 2006; Nagler, 2002). Salivary glands of rat are quite 
similar to human salivary glands in which salivary flow is rapidly reduced after radiation 
exposure (Nagler, 2002). Recent results demonstrated that histamine markedly prevented 
radiation injury on submandibular gland, ameliorating the histological and morphological 
alterations. Radiation significantly decreased salivation by approximately 35-40%, which 
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was associated with a reduction of submandibular gland wet weight and an alteration of 
epithelial architecture, vacuolization of acinar cells and partial loss of eosinophilic secretor 
granular material. It is worth noting that histamine treatment (0.1 mg.kg-1) completely 
reversed the reduced salivation induced by radiation, preserving glandular function and 
mass with normal structure organization of acini and ducts. Histamine prevented radiation-
induced toxicity in submandibular gland essentially by suppressing apoptosis of ductal and 
acinar cells, reducing the number of apoptotic cells per field (Medina et al., 2011a). 
To summarize, histamine treatment can selectively modulate cellular damage produced by 
ionising radiation, thus preventing radiation induced damage on small intestine, bone 
marrow and salivary glands. Furthermore, histamine in vitro enhances the radiosensitivity 
of breast cancer cells (Medina et al., 2006) while does not modify that of melanoma (Medina 
et al., 2007). Despite histamine may be proliferative in some cancer cell types, it may still be 
beneficial as radioprotector in view of the fact that it is only administered for a short period 
of time to reduce the radiation induced damage. It is important to highlight that histamine 
radioprotective effect was demonstrated in two different rodent species, which suggests that 
histamine could exert a radioprotective action in other mammals. Also, no local or systemic 
side effects were observed upon histamine administration in both species. 
The presented evidences indicate that histamine is a potential candidate as a safe 
radioprotective agent that might increase the therapeutic index of radiotherapy for intra-
abdominal, pelvic, and head and neck cancers, and enhance patient quality of life by 
protecting normal tissue from radiation injury. However, the efficacy of histamine needs to 
be carefully investigated in prospective clinical trials. 
9. Conclusions  
In this chapter, we have presented major findings of the most recent research in histamine 
cancer pharmacology. These data clearly indicate that histamine plays a key role as a 
mediator in most human tumours. Interestingly, histamine is not only involved in cancer 
cell proliferation, migration and invasion, but also the tumour microenvironment and 
immune system responses are tightly affected. In human neoplasias H3R and H4R seemed to 
be the main receptors involved in the control of the metabolic pathways responsible for 
tumour growth and progression, suggesting that H3R and H4R represent potential 
molecular targets for cancer drug development. Finally, a novel role for histamine as a 
selective radioprotector is highlighted, indicative of the potential application of histamine 
and its ligands as adjuvants to radiotherapy.  
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